Real-World Experience of HER2-Positive Advanced Breast Cancer (ABC) Treatment and Evaluation of Blood Biomarkers in a Public Institution in Latin America (LATAM)
Treatment sequencing has been demonstrated to enhance OS in LATAM patients with HER2-positive ABC. This study did not identify any prognostic blood biomarkers. These outcomes could influence the selection criteria for patients to receive treatment sequencing in countries without full access to innovative oncological therapies.
Authors
- Patricia Rioja (ORCID: https://orcid.org/0000-0003-3141-7418)
- Raúl Mantilla
- Tatiana Vidaurre (ORCID: https://orcid.org/0000-0003-1995-4560)
- Carlos Arturo Castañeda (ORCID: https://orcid.org/0000-0001-6200-0856)
- Silvia P. Neciosup (ORCID: https://orcid.org/0000-0002-2657-9853)
- Henry Gómez (ORCID: https://orcid.org/0000-0002-3415-9701)
- Hugo Alejandro Fuentes (ORCID: https://orcid.org/0000-0002-2747-7381)
- Zaida Morante (ORCID: https://orcid.org/0000-0003-2952-6068)
- Guillermo Valencia (ORCID: https://orcid.org/0000-0002-4234-4448)
- Mónica J. Calderón (ORCID: https://orcid.org/0000-0003-4935-7927)
- Miguel Chirito
- Olenka Peralta
Institutions
- Federico Villarreal National University (PE)
- University of Piura (PE)
- Universidad Peruana Cayetano Heredia (PE)
- Universidad Científica del Sur (PE)
- Universidad Ricardo Palma (PE)
- Instituto Nacional de Enfermedades Neoplásicas (PE)
- Centro Peruano de Estudios Sociales (PE)
Publication Details
- Journal
- Breast Cancer Basic and Clinical Research
- Published
- 2025-05-22
- DOI
- https://doi.org/10.1177/11782234251342477
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00